Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Neuren Pharmaceuticals (ASX:NEU) develops treatments for rare neurodevelopmental disorders and has faced regulatory setbacks in Europe. In February 2026, NorthStar Impact Funds noted Neuren was weak amid uncertainty about its European regulatory pathway, even as it announced an on-market buyback of up to 5% of shares. Endeavor Asset Management reported European regulators indicated trofinetide is unlikely to be approved for Rett syndrome, limiting potential sales outside the US. Earlier, Endeavor said Neuren had gained 53% after it rotated out of CSL. Neuren operates in the Healthcare sector within the Pharmaceuticals industry, and Thesis Tracker has captured 14 comments from 7 fund managers, including NorthStar and Endeavor. Founded in 2001 and headquartered in Camberwell, Melbourne, Neuren develops therapies for early childhood neurodevelopmental disorders, earning royalties from Acadia's sales of DAYBUE for Rett syndrome and developing NNZ-2591 for other rare conditions.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Endeavor Asset Management, Milford Asset Management, Spheria Asset Management, Blackwattle Investment Partners, Oracle Advisory Group, Seneca Financial Solutions and NorthStar Impact Funds have invested in Neuren Pharmaceuticals Ltd (ASX:NEU).
Fund managers point to Neuren's royalty stream from DAYBUE, its development pipeline including NNZ-2591, and an on-market buyback of up to 5% of issued capital, with Endeavor previously benefiting from a strong share price recovery.
NorthStar and Endeavor highlight European regulators indicating trofinetide is unlikely to be approved for Rett syndrome, limiting sales outside the US, along with broader regulatory uncertainty and weak sentiment.
Neuren Pharmaceuticals Ltd., founded in 2001 and headquartered in Camberwell, Australia, develops therapies for early-childhood neurodevelopmental disorders. The company operates through two segments: Commercial Products, which generates revenue from intellectual property licenses, royalties, and milestones; and Research and Development, focused on advancing clinical treatments for neurodevelopmental conditions. Neuren focuses on translating research into therapeutic solutions for neurological health.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.